Clarification of Optimal Anticoagulation Through Genetics (COAG)

This study is ongoing, but not recruiting participants.

Sponsor:

Collaborator:

Bristol-Myers Squibb

Information provided by (Responsible Party):

National Heart, Lung, and Blood Institute (NHLBI)

ClinicalTrials.gov Identifier:

NCT00839657

First received: February 6, 2009

Last updated: May 1, 2013

Last verified: May 2013

History of Changes

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Study Status:	This study is ongoing, but not recruiting participants.
Estimated Study Completion Date:	July 2013
Primary Completion Date:	April 2013 (Final data collection date for primary outcome measure)

No publications provided by National Heart, Lung, and Blood Institute (NHLBI)

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

French B, Joo J, Geller NL, Kimmel SE, Rosenberg Y, Anderson JL, Gage BF, Johnson JA, Ellenberg JH; COAG (Clarification of Optimal Anticoagulation through Genetics) Investigators. Statistical design of personalized medicine interventions: the Clarification of Optimal Anticoagulation through Genetics (COAG) trial. Trials. 2010 Nov 17;11:108.

To Top